Professional Documents
Culture Documents
14 0992 Techapp1
14 0992 Techapp1
14 0992 Techapp1
140992
International and National Guidelines for Management of Hand, Foot and Mouth
Disease (HFMD)
World Health Organization (WHO): The management algorithm of the 2011 WHO
guidelines describe 4 grades of severity: uncomplicated HFMD, HFMD with central nervous
system [CNS] complications, HFMD with autonomic nervous system [ANS] dysregulation, and
HFMD with cardiopulmonary failure. Based on anecdotal experience that intravenous
immunoglobulin (IVIg) may halt progression, if administered early, to ANS dysregulation, and
subsequently to devastating pulmonary edema (46,48; references listed with main article text).
IVIg is recommended for patients with encephalitis and flaccid paralysis, may be considered in
brainstem encephalitis. IVIg is also recommended when there are ANS dysregulations and may
be considered when there is cardiopulmonary failure and IVIg hasn’t been given yet. IVIg is not
indicated for patients with aseptic meningitis as these usually have a good prognosis (26).
Taiwan: The guidelines from Taiwan CDC 2011 describe 5 phases of disease (Phase 1:
rash, Phase 2: neural system involvement, Phase 3: pre cardiopulmonary failure, Phase 4:
cardiopulmonary failure, Phase 5: recovery). IVIg is not recommended for common phase 2
cases, but those with encephalitis or high fever and signs of pre-sepsis. For phase 3 cases, IVIg
Page 1 of 6
can be considered in patients with drowsiness and frequent myoclonic jerks, or acute paralysis,
respiratory rate >30–40 times/minutes at rest, heart rate >140–150 and signs of peripheral
perfusion insufficiency such as sweating, cold extremities, or skin color change.
Malaysia: In Malaysia there are no national guidelines. The Sibu hospital in Sarawak
uses a clinical management protocol that describes a staged approach similar to the stages used
in the Cambodia and Taiwan (51), with encephalomyelitis as stage 2 and autonomic and
cardiopulmonary dysfunction as stage 3. IVIg use is described for stage 2 and 3 but only after
lumbar puncture (showing pleiocytosis) and consultation with a pediatrician, and is said to be
less effective in stage 3. After 2011 the WHO guidelines have been adopted.
China: The 2011 consensus document from China CDC indication describes the
following indications for IVIg: symptoms of hand-food-mouth disease or herpangina, or un-
typical symptoms with consistent exposure history of enterovirus infection, and one of the
following:
• acute paralysis
• brainstem dysautonomia
• heart failure
• sepsis syndrome
IVIg is not recommended for children >5 years of age, children with multiple organ
failure and children with only meningitis but without encephalitis or paralysis, or patients with
encephalitis not caused by enterovirus. Many patients will receive IV ribavirin or traditional
Chinese medicine.
Vietnam: Vietnam uses a complicated grading system, bases on the system from Taiwan
(51), but changed considerably during the large 2011–2012 outbreak (17). Grade 2 disease (CNS
involvement) is split up in Grade 2a in which children have either a history of sporadic
Page 2 of 6
myoclonus (not seen by doctor), prolonged or high fever or vomiting. In Grade 2b disease there
are 2 groups. Group 1 has either myoclonus observed by doctor, a history of frequent myoclonus,
lethargy or tachycardia >130 (afebrile and at rest). Group 2 has either ataxia, nystagmus, limb
weakness (<4/5), cranial nerve paralysis, fever of >39°C (unresponsive to antipyretics) or
tachycardia >150 (afebrile and at rest). Grade 3 is frank ANS dysregulation and Grade 4 is
cardiopulmonary failure. Patients at grade 2a and b receive Phenobarbital to suppress myoclonus.
IVIg is indicated for grade 2b group 2 and for grade 3, for grade 2b group 1 if signs do not
improve after 6–12 hours with oral or intravenous Phenobarbital, and for grade 4 only after
shock recovery (when average blood pressure ≥50 mm Hg).
Inclusion criteria:
AND
Group A:
Having any focal neurologic signs (other than aseptic meningitis or simple febrile
seizures alone), defined as:
o Myoclonic jerks
o Limb weakness
Page 3 of 6
o Wandering eyes
OR
OR
Group B:
o hypertension: systolic blood pressure >90th percentile for age (using table)
Exclusion criteria
Severe illness meeting the criteria for the primary clinical endpoint below
Definitions
HFMD: Febrile illness with papulovesicular rash on palms and soles, with or without
vesicles/ulcers in the mouth. Rash may occasionally be maculopapular without vesicular lesion,
and may also involve the buttocks, knees or elbows, particularly in younger children and infants
(26).
Herpangina: Febrile illness with multiple oral ulcers on the posterior parts of the oral
cavity.
Page 4 of 6
Aseptic meningitis: Febrile illness with headache, vomiting and meningism associated
with presence of more than 5–10 white cells per cubic millimeter in cerebrospinal (CSF) fluid,
and negative results on CSF bacterial culture (26).
Primary Endpoints
Efficacy
tachypnea
profuse sweating
hypotension/shock
pulmonary edema/hemorrhage
cardiac arrest
Safety
Secondary endpoints
• 7-day mortality
Page 5 of 6
• duration of hospitalization
• need for rescue therapy (milrinone, CRRT/ECMO, inotropic support, other rescue
therapy)
• subgroup analysis of patients who did and did not receive phenobarbital before
randomization (part of guidelines in Vietnam)
• EV or EV71 qPCR positivity in rectal/NP swabs on day 1-2-3-4-5 or until discharge and
after 2 weeks at follow-up (all qPCRs will be performed at a single location)
• acute, before and after study drug dosage 1 and 2 and convalescent serum (after 2 weeks
at follow-up)
• cytokines (G-CSF, IL-5) levels at randomization and after 1st and 2nd study drug
• cost-effectiveness
Subsidiary studies
• qPCR positivity for enteroviruses / EV71 of blood day 1/ CSF (if collected)
• host genetics
Page 6 of 6